Evidence map›Paper›PMID 39726369›Full record

ReviewNanomedicine (London, England)2025

Nanozyme-mediated glutathione depletion for enhanced ROS-based cancer therapies: a comprehensive review.

Xinyu Wang, Nan Wei, Yang Zhang, Yuan Fang, Yijun Li, Songguo Li, Zhanggui Wang, Chenglong Sun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Targeting glutathione metabolism for tumor radiosensitization (Review).International journal of molecular medicine · 2026
    Review
  3. Phase-engineered MoSJournal of nanobiotechnology · 2026
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinyu WangSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, People's Republic of China.
Nan WeiDepartment of radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, people's Republic of China.
Yang ZhangDepartment of radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, people's Republic of China.
Yuan FangDepartment of radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, people's Republic of China.
Yijun LiDepartment of Pathology, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, People's Republic of China.
Songguo LiDepartment of Pathology, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, People's Republic of China.
Zhanggui WangDepartment of radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, people's Republic of China.
Chenglong SunDepartment of radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, people's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanozymes can improve reactive oxygen species (ROS)-based cancer therapies by targeting cancer cells' antioxidant defense mechanisms, particularly glutathione (GSH) depletion, to overcome ROS-resistant cancer cells. Nanozymes, innovative enzyme-mimetic nanomaterials, can generate ROS, alter the tumor microenvironment (TME), and synergize with photodynamic therapy (PDT), chemodynamic therapy (CDT), radiotherapy, and immunotherapy. This review shows how nanozymes catalyze ROS generation, selectively deplete GSH, and target cancer elimination, offering clear advantages over standard therapies. Nanozymes selectively target cancer cells' antioxidant defenses to improve PDT, CDT, and radiation therapies. To maximize nanozyme-based cancer treatment efficacy, biodistribution, biocompatibility, and tumor heterogeneity must be assessed. To improve cancer treatment, multifunctional, stimuli-responsive nanozymes and synergistic combination drugs should be developed.

Indexed as

GlutathioneNanostructuresNeoplasmsReactive Oxygen SpeciesAnimalsAntioxidantsHumansImmunotherapyPhotochemotherapyTumor MicroenvironmentAntioxidantsGlutathioneReactive Oxygen Speciesmultimodal cancer therapiesNanozymesnanozymes glutathione depletionreactive oxygen species (ROS)tumor microenvironment (TME)

Identifiers

PMID39726369
PMCPMC11792818

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.